NEW YORK (GenomeWeb) – Caris Life Sciences today announced a collaboration with COTA to measure the health and economic impact of the Caris Molecular Intelligence panomic tumor profiling service for cancer patients. 

Under the terms of the deal, the firms will track and combine de-identified molecular data and clinical outcomes in a longitudinal database that will be expanded across the Caris Centers of Excellence for Precision Medicine (COE) Network. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.